Longeveron

107 articles with Longeveron

• Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/10/2023

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter and full year of 2022.

• Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023

  3/6/2023

  Longeveron Inc. today announced that the Company will release its fourth quarter and full year 2022 financial results on Friday, March 10, 2023 before the open of the U.S. financial markets.

• Longeveron Appoints Wa’el Hashad as Chief Executive Officer

  2/28/2023

  Longeveron Inc. today announced the appointment of seasoned global pharmaceutical leader Wa’el Hashad as Chief Executive Officer.

• Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

  1/19/2023

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the publication of the full results from the Company’s ELPIS I trial of Lomecel-BTM for hypoplastic left heart syndrome (HLHS) in the European Heart Journal Open.

• UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

  1/6/2023

  Longeveron Inc. today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023.

• Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

  1/6/2023

  Longeveron Inc. today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023.

• Longeveron to Participate in Upcoming 2022 Investor Conferences

  11/29/2022

  Longeveron Inc., a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced that Company leadership will participate in three upcoming investor conferences.

• Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

  11/14/2022

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the third quarter ended September 30, 2022.

• Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’s Disease

  11/10/2022

  Longeveron Inc. today announced the completion of enrollment in its Phase 2a trial of Lomecel-B TM in patients with mild Alzheimer’s Disease (AD).

• Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

  11/7/2022

  Longeveron Inc., a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022 before the open of the U.S. financial markets.

• Longeveron to Present at the Annual Dawson James Small Cap Growth Conference

  10/5/2022

  Longeveron Inc. announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming Dawson James Small Cap Growth Conference taking place in Jupiter, Florida from October 11-12, 2022.

• 

  BioSpace Movers & Shakers: SOTIO, Voyager, Nutcracker and More

  9/16/2022

  Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.

• Longeveron Names Jerome Bailey Vice President of Business OperationsExecutive brings more than 30 years of global biopharmaceutical operations and program management experience

  9/15/2022

  Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it has named Jerome Bailey as the company’s new vice president of business operations.

• Longeveron to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Longeveron Inc. announced that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medical Officer at Longeveron, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place in New York City from September 12-14, 2022.

• 

  FDA Review: Immusoft, BioCryst, Intellia and More

  9/5/2022

  The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.

• U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants

  8/31/2022

  Longeveron Inc., a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced the U.S. Food and Drug Administration has granted Fast Track Designation to Lomecel-B™ for the treatment of Hypoplastic Left Heart Syndrome, a rare and life-threatening congenital heart defect affecting approximately 1,000 infants per year.

• Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™

  8/25/2022

  Longeveron Inc. today announced that the European Patent Office (EPO) has issued a notice of its intent to grant the Company a patent (EP Application No. 15861319.0) related to methods to treat endothelial dysfunction.

• Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results

  8/12/2022

  Longeveron Inc. today provided a business update and reported its financial results for the second quarter ended June 30, 2022.

• Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022Live conference call on Friday, August 12 at 8:30 a.m. EST

  8/8/2022

  Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced that the Company will release its second quarter 2022 financial results on Friday, August 12, 2022 before the open of the U.S. financial markets.

• Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)

  7/7/2022

  Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced an abstract regarding the Lomecel-B Phase 2a trial in Alzheimer’s Disease (AD) has been accepted for a poster presentation at the Alzheimer’s Association International Conference (AAIC), being held July 31-August 4, 2022 in San Diego, California, as well as virtually.